Project Details
Description
A Phase 3, single-arm, open-label, multicenter study of the safety and efficacy of dirloctocogene samoparvovec (SPK-8011, adeno-associated viral vector with B-domain deleted human factor VIII gene) in adults with severe or moderately severe hemophili
| Status | Active |
|---|---|
| Effective start/end date | 9/22/23 → 9/30/33 |
Funding
- SPARK THERAPEUTICS, INC
Fingerprint
Explore the research topics touched on by this project. These labels are generated based on the underlying awards/grants. Together they form a unique fingerprint.